BALA CYNWYD, Pa., Feb 13, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of SeraCare Life Sciences, Inc. ("SeraCare" or the "Company") (Nasdaq -SRLS- News) relating to the proposed acquisition by Linden Capital Partners ("Linden").

Under the terms of the transaction, SeraCare shareholders would receive $4.00 in cash for each share of SeraCare stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SeraCare for not acting in the Company's shareholders' best interests in connection with the sale process to Linden. The transaction may undervalue SeraCare as SeraCare stock traded at $5.45 on May 11, 2010 and traded at $4.85 as recently as January 12, 2011. In addition, an analyst has set a price target of $5.00 for each SeraCare share.

If you own shares of SeraCare stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions.  You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, visiting http://brodsky-smith.com/385-srls-seracare-life-sciences-inc.html, or by calling toll free 877-LEGAL-90.

 

SOURCE Brodsky & Smith, LLC

Back to top

RELATED LINKS
http://www.brodsky-smith.com